Browsing by Author "Baptista, F"
Now showing 1 - 4 of 4
Results Per Page
Sort Options
- Association of anti-HBc seropositivity with undetectable or low level anti-HBs (<100) in anti-HCV positive blood donor population.Publication . Barradas, A; Barra, A; Baptista, F; Soares, F; Gaspar, R; Venâncio, B; Pereira, TIn this data we observed the association between confirmed. Anti-HCV positive and Anti-HBc positive with low level (<100) or undetectable Anti-HBs. b) ./. c) Between May 1995 to December 2001 we collected and analysed 24989 samples from volunteer blood donors. In this samples we performed the following tests Anti?HCV (Ortho), confirmed for PCR (Roche) or RIBA (Innogenetics), Anti-HBc (Dade-Behreing/Abbott, Anti-HBs (Abbott) and HCV genotype (Innogenetics). d) We found between Anti-HCV neg. population 6,94% positives Anti-HBc and 25,65% of them was Anti-HBs low level or undetectable. In the population we found 0,148% of confirmed Anti-HCV reactive donors, among them we found 51,35% of Anti-HBc positivity and between the last ones 78,9% had low level or undetectavel Anti-HBs. The ALT average level in the Anti-HCV positive donors was: Anti-HBc negative donors: 140,28 Ani-HBc positives with high level of Anti-HBs: 50,48 Anti-HBc positives with low or undetectable level of Anti-HBs: 64,11 e) The Anti-HCV confirmed donors associated to the Anti-HBc positives with low level or undetectable Anti-HBs (78,9%). Comparing with the Anti-HCV negative donors, positive for Anti?HBc and with low level or undetectable Anti-HBs (25,65%). This is statistically relevant.
- Detecção de Ag B19 numa população de dadores de sanguePublication . Barradas, A; Mercês, A; Barra, A; Baptista, F; Pereira, F; Santos, F; Soares, F; Pereira, TObjecto do estudo: Prevalência do Ag B19 numa população de dadores de sangue. Métodos utilizados: Entre Agosto e Dezembro de 2000 foram analisados no Serviço de Imuno-hemoterapia do Hospital Fernando da Fonseca 708 dadores para a detecção do Ag B19. O teste utilizado foi um teste de hemaglutinação em gel, utilizando células sensibilizadas, que na presença de partículas do B19 (contidas no soro/plasma do dador) aglutinam (ID-Parvovírus B19-DiaMed). Os dadores estudados tinham idades compreendidas entre os 18 e os 65 anos, sendo maioritariamente do sexo masculino, todos foram submetidos a consulta pré-dádiva e aprovados pelo médico. As amostras colhidas foram submetidas a controlo analítico para antigenémia do HBV, ac. anti-HBc, ac. Anti-HBs, ac.anti-HCV, ac. anti-CMV, ac. anti-HIV 1 e 2, VDRL, ALT (GPT) e PCR para o HCV. Resultados: Três dadores tiveram testes positivos para os AgB19 (0,424%), pertencendo todos ao sexo masculino e com idades compreendidas entre os 40 e os 49 anos, como marcadores concomitantemente positivos, havia um com acs. Positivos para o CMV, outro com GPT elevada e acs. anti-HBc, anti-HBs e anti-CMV positivos, o terceiro era negativo para todos os marcadores. Conclusões: Do nosso estudo não podemos concluir que exista uma correlação entre antigenémia positiva para o Parvovírus B19 e positiva para outros marcadores. Temos que, no futuro, avaliar da pertinência da execução deste teste em rotina de Banco de Sangue, aquando da transfusão de grávidas, recém-nascidos ou doentes imunodeprimidos.
- Programa educativo pré-alta: impacto de um programa educativo para doentes após AVC e cuidadores informais no momento da alta hospitalar: estudo exploratórioPublication . Damião, L; Baptista, F; Pereira, C; Alves, A; Silva, A; Carvalho, A; Vera-Cruz, C; Patinha, B; Pires, F; Prates, L; Ferreira, M; Silva, V
- A retrospective study of B19 positive antigen blood donationsPublication . Mercês, A; Estevens, A; Barradas, A; Barra, A; Baptista, F; Soares, FBetween August and December 2000 using ID-Parvovirus B19 – DiaMed, we studied 708 blood donations to detect b19 Ag on the plasma kept in our serum colletion, we found a prevalence of 0,424% positive donations. Globoside, a P blood group antigen, is the major red blood cell receptor used by b19 for attachment and entry into the cell. This is why we have included it in our study. We performed the retrospective study in this blood components: Obtained results in blood donors (see poster). Obtained results of transfused patients with blood components from those donors (see poster). Conclusions: As it is possible to see in our results, one of the patients was infected recently by one blood unit. Our objective is not to transfuse this positive blood components to patients in risk, like individuals with underlying haemolytic disorders, immunocompromised patients, immunodeficient individuals, pregnant women, fetus and newborns. Other measures may be implemented, like: deferral permanently those donors, or researche P Ag in all patients?